Safety, tolerability, and pharmacokinetics of crenezumab in patients with mild-to-moderate Alzheimer’s disease treated with escalating doses for up to 133 weeks
Manuscript Number:
20-0134R1
Author(s):
Tobias Bittner, Kathleen Blondeau, Montserrat Carrasco-Triguero, David Clayton, Michael Dolton, Heather Guthrie, Lawrence S. Honig, Qinshu Lian, Helen Lin, Susanne Ostrowitzki, Angelica Quartino, Kaycee M. Sink, Jillian Smith
Disclosures
Tobias Bittner
Sponsors:
Full-time employee of F. Hoffmann-La Roche Ltd.
Kathleen Blondeau
Sponsors:
Full-time employee of F. Hoffmann-La Roche Ltd.
Montserrat Carrasco-Triguero
Sponsors:
Full-time employee of Genentech, Inc.
David Clayton
Sponsors:
Full-time employee of Genentech, Inc.
Michael Dolton
Sponsors:
Full-time employee of Genentech, Inc.
Heather Guthrie
Sponsors:
Full-time employee of Genentech, Inc.
Lawrence S. Honig
Consulting Fees:
Consultant for Eisai and Miller Communications and study investigator for AbbVie, Biogen, Bristol-Myers Squibb, Eisai, Eli Lilly, Genentech, Inc., Lundbeck, F. Hoffmann-La Roche Ltd, and vTv Therapeutics, Inc.